Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms 2Lymphoma 2Glioma 2Brain Neoplasms 2Leukemia, Lymphoid 1Disease Progression 1

Interventions

Temozolomide 38Radiotherapy 22Radiosurgery 22Radiation 11Magnetic Resonance Spectroscopy 11Irinotecan 11Cyclophosphamide 11Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9pembrolizumab 8Filgrastim 8Carboplatin 8Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Lomustine 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × enzastaurin × Clear all
NCT00108056 2019-12-05

Enzastaurin to Treat Recurrent Brain Tumor

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
26 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Disease Progression

NCT01445119 2013-08-28

A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas

Eli Lilly and Company

Phase 1 Completed
58 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡